Law360, New York (November 10, 2009) -- A federal judge has dismissed fraud claims from a suit brought by a putative class of patients and Zurich Insurance Co. alleging that biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a valid remedy for a lung disease it is not approved to treat.
After dismissing the first amended complaint and allowing the plaintiffs to refile, Judge Marilyn Patel dismissed state-law fraud claims from the lawsuit with prejudice Friday in the U.S. District Court...
